JB
ROIV icon

Julian Baker’s Roivant Sciences ROIV Stock Holding History

Julian Baker’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$167M Sell
4,716,831
-150,892
-3% -$4.46M 0.84% 19
2026
Q1 		$135M Sell
4,867,723
-687,294
-12% -$17.7M 0.77% 19
2025
Q4 		$121M Buy
5,555,017
+1,787,244
+47% +$35.3M 0.71% 21
2025
Q3 		$57M Hold
3,767,773
– – 0.41% 26
2025
Q2 		$42.5M Hold
3,767,773
– – 0.41% 28
2025
Q1 		$38M Hold
3,767,773
– – 0.42% 27
2024
Q4 		$44.6M Buy
3,767,773
+969,057
+35% +$11.5M 0.48% 27
2024
Q3 		$32.3M Hold
2,798,716
– – 0.33% 33
2024
Q2 		$29.6M Sell
2,798,716
-4,615,118
-62% -$50.6M 0.38% 34
2024
Q1 		$78.1M Sell
7,413,834
-179,190
-2% -$1.93M 0.98% 13
2023
Q4 		$85.3M Sell
7,593,024
-4,284,147
-36% -$41.8M 0.97% 12
2023
Q3 		$139M Buy
11,877,171
+2,448,579
+26% +$27.7M 0.8% 8
2023
Q2 		$95M Buy
9,428,592
+4,651,162
+97% +$41.6M 0.55% 16
2023
Q1 		$35.3M Buy
4,777,430
+4,060,777
+567% +$33.4M 0.19% 27
2022
Q4 		$5.73M Buy
+716,653
New +$3.99M 0.03% 76

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Julian Baker's ROIV Position: Q2 2026 in Review

Julian Baker reduced its Roivant Sciences (ROIV) stake by 3.1% in Q2 2026, selling an estimated $4.46M and leaving 4,716,831 shares worth $167M. The position accounts for 0.84% of the portfolio, ranked #19.

Julian Baker first reported a position in ROIV in Q4 2022 and has held it in 15 quarters since. 495 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Julian Baker held 4,716,831 shares of Roivant Sciences worth $167M as of Q2 2026.
  • Julian Baker sold 150,892 Roivant Sciences shares in Q2 2026, an estimated $4.46M.
  • Roivant Sciences made up 0.84% of Julian Baker's portfolio in Q2 2026, its #19 holding.
  • Julian Baker first reported a position in Roivant Sciences in Q4 2022 and has held it in 15 quarters since.
  • 495 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Baker Bros. Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.